Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
Site Search
Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 study results for Trikafta® (elexacaftor/tezacaftor/ivacaftor) for people with cystic fibrosis ages 12 years and older who have one copy of the F508del mutation and one gating or residual function mutation.
The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.
On Mar. 11, the Cystic Fibrosis Foundation presented the Alex, Jena and Dream Big Awards to leaders in the CF community for their dedication to the Foundation's mission of finding a cure.
Ginger Birnbaum and Mike Beatty lead efforts in Dallas for banner conference -- "teamMATEs for a Cure.”
Choate Construction's National Corporate Team raised over $670,000 for the Cystic Fibrosis Foundation in 2019, serving as a role model for corporations looking to integrate philanthropy into their business model.
On the heels of exciting progress in the fight against CF, more than 500 of the Cystic Fibrosis Foundation's most dedicated volunteers, chapter staff and corporate supporters came together at the 12th annual CF Volunteer Leadership Conference, and hundreds more watched via live stream March 20-21.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.